GSK licensed exclusive worldwide rights to SiranBio’s siRNA SA-030 in a deal potentially worth up to $1 billion. The program targets ALK7 with the intent to reduce abdominal fat and improve cardiometabolic risk in patients with chronic lung, liver, and kidney diseases. GSK’s agreement centers on SA-030’s Phase 1 stage progress and ongoing development, with the pharma set to make milestones tied to regulatory and commercial achievements plus tiered royalties. The company positioned the move as further expansion of its oligonucleotide pipeline in metabolic disease. Arrowhead Pharmaceuticals is separately investigating an ALK7 gene silencing strategy, underscoring converging mechanistic efforts across RNA-based platforms for abdominal fat reduction. For the biotech sector, the transaction signals how leading pharma are continuing to build obesity and cardiometabolic intellectual property not only through GLP-1 franchises but also through RNAi and tissue-targeting mechanisms that may differentiate in long-term metabolic outcomes.